iTolerance is a biotechnology company developing a synthetic immunomodulatory platform that enables tissue and cell therapies without the need for lifelong immunosuppression. Their proprietary technology, including the iTOL-100 product, aims to induce durable immune tolerance, potentially providing cures for diseases such as Type 1 Diabetes.
Funding
$17.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell and tissue therapies often require patients to take lifelong immunosuppressive drugs to prevent rejection, leading to increased risk of infection and other complications. Current methods for inducing immune tolerance are often insufficient, limiting the widespread adoption of regenerative medicine approaches.
Solution
iTolerance is developing a synthetic immunomodulatory platform designed to enable cell and tissue therapies without the need for chronic immunosuppression. Their lead technology, iTOL-100, is a synthetic form of the naturally occurring protein FasL combined with a synthetic biotin-PEG microgel. This platform allows for co-administration with implanted cells or organoids to induce durable immune tolerance. By leveraging this technology, iTolerance aims to create therapies that can potentially cure diseases by eliminating the need for continuous immune suppression.
Target Audience
The primary target audience includes researchers and clinicians in the fields of regenerative medicine, cell therapy, and transplantation, specifically those focused on autoimmune diseases like Type 1 Diabetes and organ failure.
Features
- iTOL-100: A synthetic FasL protein combined with a biotin-PEG microgel for targeted immune modulation.
- Co-administration with cell or organoid therapies to promote localized immune tolerance.
- Pipeline programs include iTOL-101 and iTOL-102 for Type 1 Diabetes, utilizing allogeneic cadaveric pancreatic islets and stem cell-derived human pancreatic islets, respectively.
- iTOL-201: Focuses on liver function regeneration.
- iTOL-401: Designed for large organ transplantation.